Hemogenyx Pharmaceuticals PLC Announces Presentation at CBD S&T Conference
Hemogenyx Pharmaceuticals plc (LSE:HEMO), a clinical-stage biopharmaceutical company, has been invited to present at the 2024 Chemical and Biological Defense Science & Technology (CBD S&T) Conference in Fort Lauderdale, FL, from December 2-5, 2024. The company will showcase its Chimeric Bait Receptor (CBR) platform, an advanced immunotherapy designed to reprogram innate immune cells to combat viral infections and specific types of cancer.
The presentation, titled 'Chimeric Bait Receptor (CBR) for Reprogramming of Myeloid Cells to Target and Eliminate Emerging Viral Infections', will focus on the platform's application in fighting viral threats. Dr. Vladislav Sandler, CEO & Co-Founder, emphasized the opportunity to establish Hemogenyx's position in the biodefense field and engage with experts, potential collaborators, and investors.
Hemogenyx Pharmaceuticals plc (LSE:HEMO), un'azienda biofarmaceutica in fase clinica, è stata invitata a presentare alla Conferenza 2024 sulla Scienza e Tecnologie per la Difesa Chimica e Biologica (CBD S&T) che si terrà a Fort Lauderdale, FL, dal 2 al 5 dicembre 2024. L'azienda mostrerà la sua piattaforma Chimeric Bait Receptor (CBR), un'immunoterapia avanzata progettata per riprogrammare le cellule immunitarie innate per combattere le infezioni virali e specifici tipi di cancro.
La presentazione, intitolata 'Chimeric Bait Receptor (CBR) per la riprogrammazione delle cellule mieloidi per mirare ed eliminare le infezioni virali emergenti', si concentrerà sull'applicazione della piattaforma nella lotta contro le minacce virali. Il Dott. Vladislav Sandler, CEO e Co-Fondatore, ha sottolineato l'opportunità di stabilire la posizione di Hemogenyx nel campo della biodefesa e di interagire con esperti, potenziali collaboratori e investitori.
Hemogenyx Pharmaceuticals plc (LSE:HEMO), una empresa biofarmacéutica en etapa clínica, ha sido invitada a presentar en la Conferencia 2024 de Ciencia y Tecnología para la Defensa Química y Biológica (CBD S&T) en Fort Lauderdale, FL, del 2 al 5 de diciembre de 2024. La compañía mostrará su plataforma Chimeric Bait Receptor (CBR), una inmunoterapia avanzada diseñada para reprogramar las células inmunitarias innatas para combatir infecciones virales y tipos específicos de cáncer.
La presentación, titulada 'Chimeric Bait Receptor (CBR) para la reprogramación de células mieloides para atacar y eliminar infecciones virales emergentes', se centrará en la aplicación de la plataforma en la lucha contra amenazas virales. El Dr. Vladislav Sandler, CEO y Co-Fundador, enfatizó la oportunidad de establecer la posición de Hemogenyx en el campo de la biodefensa y de interactuar con expertos, potenciales colaboradores e inversores.
헤모제닉스 제약 plc (LSE:HEMO), 임상 단계의 바이오 제약 회사가 2024 화학 및 생물학적 방어 과학 및 기술(CBD S&T) 컨퍼런스에 발표하도록 초청받았습니다. 이 컨퍼런스는 2024년 12월 2일부터 5일까지 플로리다주 포트 로더데일에서 열립니다. 회사는 키메라 미끼 수용체(CBR) 플랫폼, 바이러스 감염과 특정 유형의 암을 퇴치하기 위해 내재 면역 세포를 재프로그래밍하기 위해 설계된 진보된 면역 치료법을 선보일 것입니다.
‘키메라 미끼 수용체(CBR)를 통한 골수 세포의 재프로그래밍으로 신흥 바이러스 감염을 타겟하고 제거하기’라는 제목의 발표는 플랫폼의 바이러스 위협 대응 응용에 초점을 맞출 것입니다. 블라디슬라프 샌들러 박사, CEO 및 공동 창립자는 헤모제닉스의 생물 방어 분야에서의 입지를 확립하고 전문가, 잠재적인 협력자 및 투자자와의 교류 기회를 강조했습니다.
Hemogenyx Pharmaceuticals plc (LSE:HEMO), une entreprise biopharmaceutique en phase clinique, a été invitée à présenter lors de la Conférence 2024 sur la Science et la Technologie de la Défense Chimique et Biologique (CBD S&T) à Fort Lauderdale, FL, du 2 au 5 décembre 2024. L'entreprise présentera sa plateforme Chimeric Bait Receptor (CBR), une immunothérapie avancée conçue pour reprogrammer les cellules immunitaires innées afin de lutter contre les infections virales et certains types de cancer.
La présentation, intitulée 'Chimeric Bait Receptor (CBR) pour la reprogrammation des cellules myéloïdes pour cibler et éliminer les infections virales émergentes', se concentrera sur l'application de la plateforme dans la lutte contre les menaces virales. Dr. Vladislav Sandler, PDG et cofondateur, a souligné l'opportunité de renforcer la position de Hemogenyx dans le domaine de la biodefense et d'interagir avec des experts, des potentiels collaborateurs et des investisseurs.
Hemogenyx Pharmaceuticals plc (LSE:HEMO), ein biopharmazeutisches Unternehmen in der klinischen Phase, wurde eingeladen, auf der 2024 Chemical and Biological Defense Science & Technology (CBD S&T) Konferenz in Fort Lauderdale, FL, vom 2. bis 5. Dezember 2024 zu präsentieren. Das Unternehmen wird seine Chimeric Bait Receptor (CBR) Plattform vorstellen, eine fortschrittliche Immuntherapie, die darauf abzielt, angeborene Immunzellen umzuprogrammieren, um virale Infektionen und spezifische Krebsarten zu bekämpfen.
Die Präsentation mit dem Titel 'Chimeric Bait Receptor (CBR) zur Reprogrammierung myeloider Zellen zur Zielgerichteten Bekämpfung und Eliminierung aufkommender Virusinfektionen' wird sich auf die Anwendung der Plattform im Kampf gegen virale Bedrohungen konzentrieren. Dr. Vladislav Sandler, CEO und Mitbegründer, betonte die Gelegenheit, die Position von Hemogenyx im Bereich der Biodefense zu festigen und mit Experten, potenziellen Partnern und Investoren in Kontakt zu treten.
- Invited to present at a prestigious biodefense conference, showcasing the company's technology
- Developing an advanced immunotherapy platform (CBR) with potential applications in cancer and viral infections
- Opportunity to network with biodefense experts, potential collaborators, and investors
- None.
LONDON, UNITED KINGDOM / ACCESSWIRE / August 28, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the clinical-stage biopharmaceutical group developing treatments for cancers and viral diseases, is pleased to announce its participation in the 2024 Chemical and Biological Defense Science & Technology ("CBD S&T") Conference, which will be held on December 2-5, 2024, in Fort Lauderdale, FL.
The Company competed for a presentation slot and was invited to present its work on its proprietary Chimeric Bait Receptor ("CBR") platform for combating viral infections. The presentation is entitled "Chimeric Bait Receptor (CBR) for Reprogramming of Myeloid Cells to Target and Eliminate Emerging Viral Infections".
The Company's CBR platform is an advanced immunotherapy designed to program or redirect innate immune cells, such as macrophages, to eliminate specific types of cancer as well as to combat infections from both existing and emerging viral threats. The Company's presentation at the CBD S&T conference will focus on the use of the CBR platform for combating viral infections.
Dr. Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: "Our presentation at the CBD S&T conference will provide the Company with an opportunity to further establish its unique position in the rapidly evolving field of biodefense. It will also allow us to exchange ideas with like-minded biodefense experts, potential collaborators, and investors."
Enquiries:
Hemogenyx Pharmaceuticals plc | |
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder | |
Peter Redmond, Director | |
|
|
SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
Matthew Johnson, Vadim Alexandre, Adam Cowl |
|
|
|
Peterhouse Capital Limited | Tel: +44 (0)20 7469 0930 |
Lucy Williams, Duncan Vasey, Charles Goodfellow |
|
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.
The Company is a clinical-stage biopharmaceutical group developing new medicines and treatments for life-threatening diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Hemogenyx Pharmaceuticals PLC
View the original press release on accesswire.com
FAQ
What is Hemogenyx Pharmaceuticals presenting at the 2024 CBD S&T Conference?
When and where is the 2024 CBD S&T Conference taking place?
What is the potential application of Hemogenyx's CBR platform?
What is Hemogenyx Pharmaceuticals' stock symbol on the London Stock Exchange?
